GLP-2 (human)

GLP-2(1-33) (human) is an enteroendocrine hormone that stimulates intestinal epithelium growth.

GLP-2 (1-34) (human) 是一种肠道多肽，其在进食后数分钟内释放，并可用于研究骨重塑过程。

Semaglutide 是人胰高血糖素样肽-1受体激动剂，是一种人胰高血糖素样肽-1 的长效类似物。它有用于 2 型糖尿病研究的潜力。

GLP-1 amide is a peptide hormone cleaved from proglucagon in the pancreas.1,2 Mice lacking the glucagon receptor (Gcgr-/-) have approximately nine-fold higher levels of total GLP-1 amide, including GLP-1 (1-36) amide and truncated GLP-1 (7-36) amide , in pancreatic tissue compared to wild-type mice.2References1. Schjoldager, B.T., Mortensen, P.E., Christiansen, J., et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34(5), 703-708 (1989).2. Gelling, R.W., Du, X.Q., Dichmann, D.S., et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100(3), 1438-1443 (2003). GLP-1 amide is a peptide hormone cleaved from proglucagon in the pancreas.1,2 Mice lacking the glucagon receptor (Gcgr-/-) have approximately nine-fold higher levels of total GLP-1 amide, including GLP-1 (1-36) amide and truncated GLP-1 (7-36) amide , in pancreatic tissue compared to wild-type mice.2 References1. Schjoldager, B.T., Mortensen, P.E., Christiansen, J., et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34(5), 703-708 (1989).2. Gelling, R.W., Du, X.Q., Dichmann, D.S., et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100(3), 1438-1443 (2003).

PACAP-related peptide (PRP) is an endogenous 29-amino acid peptide that belongs to the secretin/glucagon superfamily of peptides, which includes secretin , glucagon , glucagon-like peptide-1 , GLP-2 , and pituitary adenylate cyclase-activating polypeptide . It is expressed in normal human pancreas and adrenal gland tissue and in some tumors that produce vasoactive intestinal peptide (VIP). PRP (1-29) is secreted by CHO-K1 cells that express human recombinant preproPACAP.

GLP-1(9-36)amide TFA, 作为胰高血糖素样肽-1 (7-36)amide的主要代谢产物，是人胰腺GLP-1受体的拮抗剂。

Beinaglutide 是一种重组人 GLP-1(rhGLP-1) 多肽，与人 GLP-1(7-36) 具有几乎 100% 的同源性。Beinaglutide 在血糖控制、抑制食物摄入和胃排空和促进体重减轻方面表现出依赖于剂量的作用。Beinaglutide 具有研究超重/肥胖和非酒精性脂肪性肝炎 (NASH) 的潜力。

Albiglutide fragment (GLP-1 (7-36) analog) TFA为Albiglutide活性片段，代表胰高血糖素样肽-1(GLP-1)模拟物，属长效GLP-1受体激动剂。由GLP-1二聚体抗DPP-4特性与人白蛋白基因融合而成，本化合物在降低糖化血红蛋白(A1C)方面表现显著，主要应用于2型糖尿病(T2D)的相关研究。

Tirzepatide 是一种glucagon-like peptide 1 receptor (GLP-1R) 和 G protein-coupled receptor 119 (GPR119)的激动剂。它在表达人类GLP-1R或GPR119的HEK293细胞中诱导cAMP的产生（EC50s分别为6.54和1.01 nM）。Tirzepatide（100 nM）在表达人类GLP-1R或GPR119的HEK293细胞中诱导受体内化。在体内，Tirzepatide（每天10 nmol/kg）降低高脂饮食诱导的肥胖小鼠模型的体重、食物摄入量、血浆leptin、三酸甘油酯和free fatty acids (FFAs)水平、肝脏三酸甘油酯和血糖水平。它通过每三天给药50 nmol/kg的剂量，阻止A. alternata诱导的A. alternata挑战小鼠的支气管肺泡灌洗液（BALF）中嗜酸性粒细胞和淋巴细胞数量的增加。Tirzepatide（每三天50 nmol/kg）抑制由毒蕈碱受体激动剂methacholine (acetyl-β-methylcholine)导致的在糖尿病诱导的哮喘小鼠模型中的支气管收缩。含Tirzepatide的制剂已用于治疗2型糖尿病。

Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently Glucagon-Like Peptide 2 is used as a po

GEP44 是一种肽偏向的三重激动剂，针对胰高血糖素样肽 1 受体 (GLP-1R)、神经肽 Y1 受体 (Y1-R) 和神经肽 Y2 受体 (Y2-R)。该化合物通过抵消 Y1-R 和 GLP-1R 的激动作用，诱导大鼠和人类胰岛中 Y1-R 拮抗剂调控的 GLP-1R 依赖性胰岛素分泌刺激。GEP44 还促进肌肉组织中的胰岛素非依赖性 Y1-R 介导的葡萄糖摄取，显著减少饮食诱导的肥胖大鼠模型的食物摄入和体重。GEP44 可用于研究肥胖和 2 型糖尿病。